WeVote
Log In

Bill

Bill

A 4957

Authorizes prescription of Schedule II controlled dangerous substances through telemedicine or telehealth without certain in-person requirements.

2026-2027 Regular Session Introduced by Chris Tully

Allows prescribing Schedule II controlled substances via telemedicine without certain in-person visits, under standard safety and regulatory rules.

Introduced, Referred to Assembly Health Committee
0
WeVote Research Nonpartisan
Bill Summary · A 4957

Summary of New Jersey Assembly Bill A4957 (Session 222)

Title

Authorizes prescription of Schedule II controlled dangerous substances through telemedicine or telehealth without certain in-person requirements.

Purpose and intent

  • The bill aims to expand access to Schedule II controlled substances by allowing clinicians to prescribe these medications via telemedicine or telehealth platforms without the need for certain in-person evaluations that are otherwise required under current law.
  • The underlying goal is to improve patient access to essential medications while maintaining appropriate clinical oversight.

Key provisions and changes

  • Prescribing authority via telemedicine: Enables a licensed healthcare professional to prescribe Schedule II controlled dangerous substances (CDS) through telemedicine or telehealth without the traditional in-person visit requirement that is typically mandated for such prescriptions.
  • Scope of Schedule II substances: Applies to federally designated Schedule II CDS. (The bill references these substances without listing specific drugs, aligning with standard Schedule II classifications under the DEA schedule system.)
  • Clinical standards: The prescription must be issued in accordance with professional practice standards and applicable state and federal regulations governing telemedicine, patient safety, and prescription authority.
  • Prescriber requirements: Prescribers must be appropriately licensed in New Jersey and acting within their scope of practice. They may need to verify patient identity and ensure continuity of care through telemedicine.
  • Patient safety and monitoring: The bill implicitly supports mechanisms for record-keeping, monitoring, and review to mitigate misuse, consistent with telemedicine best practices. It may reference standard prescribing safeguards, such as:
    • Prescription monitoring through the state’s Prescription Monitoring Program (if applicable)
    • Documentation of clinical justification, diagnosis, and treatment plan
    • Compliance with dosing, duration, and dispensing regulations for Schedule II substances
  • Fees and penalties: The bill would align with existing enforcement provisions for CDS prescribing; violations could result in professional discipline, penalties, or loss of license, consistent with current New Jersey law.

Who/what is affected

  • Healthcare providers: Licensed physicians, advanced practice nurses, and other prescribers authorized to issue Schedule II CDS in New Jersey, who use telemedicine or telehealth.
  • Patients seeking Schedule II CDS: Individuals who require access to Schedule II medications and are using telemedicine services for their care.
  • Telemedicine/telehealth platforms: Platforms that facilitate remote consultations and prescribing activity for Schedule II CDS, subject to state regulatory compliance.
  • Regulatory and oversight entities: State medical boards, pharmacy boards, and agencies responsible for prescription monitoring and enforcement of CDS regulations.

Procedural and timeline aspects

  • Effective date and implementation: The bill would specify an effective date on enactment and outline any phased or immediate applicability for telemedicine-prescribed Schedule II CDS, subject to regulatory rulemaking or guidance.
  • Regulatory alignment: Likely requires alignment with existing New Jersey telemedicine statutes and prescription monitoring requirements, potentially prompting updates to administrative rules or guidance.
  • Oversight and sunset (if any): The summary does not indicate a sunset clause; any such provisions would be defined in the final text. Ongoing oversight by relevant professional boards and possibly the state Department of Health or Board of Medical Examiners would apply.
  • Relationship to federal law: While state law governs state-licensed prescribers, Schedule II substances are federally regulated. The bill operates within that framework, ensuring telemedicine prescribing remains compliant with federal scheduling and DEA regulations.

Notes

  • This summary focuses on the substantive intent and likely effects based on the bill’s title and sponsor information. For precise language (definitions, allowed exceptions, patient safety safeguards, and any reporting requirements), please refer to the official bill text and any fiscal or statutory analyses released by the New Jersey Legislature.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.